Methods for treating conditions associated with c-fms
Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.
1. A method for treating cancer in a cancer patient comprising administering an effective amount of an antibody or antibody fragment to the patient, wherein
(a) the antibody or antibody fragment binds human c-fms and comprises:
(i) a heavy chain variable domain comprising a CDRH1, a CDRH2 and a CDRH3, wherein the CDRH1 comprises the amino acid sequence of SEQ ID NO:147, the CDRH2 comprises the amino acid sequence of SEQ ID NO:163, and the CDRH3 comprises the amino acid sequence of SEQ ID NO:186; and
(ii) a light chain variable domain comprising a CDRL1, a CDRL2 and a CDRL3, wherein the CDRL1 comprises the amino acid sequence of SEQ ID NO:193; the CDRL2 comprises the amino acid sequence of SEQ ID NO:214 and the CDRL3 comprises the amino acid sequence of SEQ ID NO:228; and
(b) the cancer is selected from the group consisting of breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell cancer, uveal melanoma, follicular lymphoma, renal cancer, cervical cancer, gastric cancer, astrocytic cancer, lung cancer, ovarian cancer, and colorectal cancer.
2. The method of claim 1 , wherein the antibody or fragment has one or more of the following characteristics:
(a) is a monoclonal antibody;
(b) is a chimeric, a humanized or a fully human antibody;
(c) is an antibody of the IgG1-, IgG2-, IgG3- or IgG4-type;
(d) is a Fab fragment, a Fab′ fragment, an F(ab′)2 fragment, or an Fv fragment.
3. The method of claim 1 , wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, lung cancer, ovarian cancer, and colorectal cancer.
4. A method for treating cancer in a cancer patient comprising administering an effective amount of an antibody or antibody fragment to the patient, wherein
(a) the antibody or antibody fragment binds human c-fms and comprises:
(i) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:77; and
(ii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:110; and
(b) the cancer is selected from the group consisting of breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell cancer, uveal melanoma, follicular lymphoma, renal cancer, cervical cancer, gastric cancer, astrocytic cancer, lung cancer, ovarian cancer, and colorectal cancer.
5. The method of claim 4 , wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, lung cancer, ovarian cancer, and colorectal cancer.
6. A method for treating cancer in a cancer patient comprising administering an effective amount of an antibody or antibody fragment to the patient, wherein
(a) the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:11 and the light chain comprises the amino acid sequence of SEQ ID NO:44; and
(b) the cancer is selected from the group consisting of breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell cancer, uveal melanoma, follicular lymphoma, renal cancer, cervical cancer, gastric cancer, astrocytic cancer, lung cancer, ovarian cancer, and colorectal cancer.
7. The method of claim 6 , wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, lung cancer, ovarian cancer, and colorectal cancer.
8. A method for treating cancer in a cancer patient comprising administering an effective amount of an antibody or antibody fragment to the patient, wherein
(a) the antibody or antibody fragment is an antibody or antibody fragment that competes with a reference antibody for binding to the extracellular domain of human c-fms of SEQ ID NO:1, and wherein the reference antibody comprises:
(i) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:77; and
(ii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:110; and
(b) the cancer is selected from the group consisting of breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell cancer, uveal melanoma, follicular lymphoma, renal cancer, cervical cancer, gastric cancer, astrocytic cancer, lung cancer, ovarian cancer, and colorectal cancer.
9. The method of claim 8 , wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, lung cancer, ovarian cancer, and colorectal cancer.
10. The method of claim 1 , wherein the cancer is breast cancer, prostate cancer or lung cancer.
11. The method of claim 4 , wherein the cancer is breast cancer, prostate cancer or lung cancer.
12. The method of claim 6 , wherein the cancer is breast cancer, prostate cancer or lung cancer.
13. The method of claim 8 , wherein the cancer is breast cancer, prostate cancer or lung cancer.